NDAORALTABLET
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZYDELIG (idelalisib) by Gilead Sciences is kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2014.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYDELIG (idelalisib) is an oral small-molecule phosphatidylinositol 3-kinase (PI3K) delta inhibitor approved in 2014 for hematologic malignancies. It works by blocking PI3K signaling, a pathway critical to B-cell survival and proliferation. The drug is used in combination therapies for chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma.
Peak7.2 years to LOE
Product is at peak lifecycle stage within mature kinase inhibitor market; commercial team likely stable with focus on market maintenance rather than growth expansion.
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
Started Nov 2021
6 enrolled
Relapsed Follicular LymphomaRefractory Follicular Lymphoma
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Started Mar 2021
238 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Started Oct 2020
0Chronic Lymphocytic LeukemiaCLLRelapsed CLL+6 more
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
Started Oct 2019
5 enrolled
Follicular Lymphoma
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Started Jun 2019
0Diffuse Large B-Cell LymphomaMediastinal B-cell Lymphoma
Worked on ZYDELIG at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.